Skip to main content
Onconic Therapeutics Inc. logo

Onconic Therapeutics Inc. — Investor Relations & Filings

Ticker · 476060 ISIN · KR7476060009 KO Manufacturing
Open in API
Filings indexed 125 across all filing types
Latest filing 2025-08-22 Report Publication Anno…
Country KR South Korea
Listing KO 476060

About Onconic Therapeutics Inc.

http://onconic.co.kr/

Onconic Therapeutics Inc., established in 2020, is a biopharmaceutical company specializing in the research and development of innovative drugs. A subsidiary of Jeil Pharmaceutical, the company focuses on creating novel treatments for cancer and gastrointestinal disorders, including gastroesophageal reflux disease. Its development strategy prioritizes therapeutics for conditions with high unmet medical needs and significant market potential. Onconic Therapeutics actively advances its pipeline of drug candidates through various stages of clinical trials.

Recent filings

Filing Released Lang Actions
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a short announcement regarding an upcoming Investor Relations (IR) event (a Non-Deal Roadshow or NDR). It specifies the date, location, purpose, and target audience for the meeting. Since it is an announcement of an event rather than the presentation materials themselves, and it does not fit into other specific categories like 'Investor Presentation' (which would contain the actual slides), it is classified as a Regulatory Filing (RNS) as it serves as a formal notice of corporate activity.
2025-08-22 Korean
투자판단관련주요경영사항 (파트너사인 Livzon Pharmaceutical Group Inc.에 Zastaprazan(자큐보정)의 중국 임상3상 성공 및 품목허가 신청 마일스톤 달성에 따른 기술료 청구)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Onconic Therapeutics regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It details the achievement of a clinical trial milestone (Phase III completion and marketing authorization submission) by a partner company, Livzon Pharmaceutical Group, and the subsequent billing of a milestone payment. This type of disclosure, which reports on specific business events, contract milestones, and financial impacts, is classified as a general regulatory filing (RNS) within the Korean stock exchange (KIND) framework, as it does not fit into more specific categories like earnings releases or annual reports.
2025-08-19 Korean
투자판단관련주요경영사항(임상시험계획변경승인신청) (네수파립의 췌장암 제1b/2상 임상시험계획승인(변경승인)신청))
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (Onconic Therapeutics) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically an application for a change in clinical trial approval (임상시험계획 변경승인신청) for a drug candidate. This type of disclosure is a standard regulatory announcement for material corporate events in the Korean market. Since it does not fit into specific categories like M&A, dividends, or financial reports, it falls under the general regulatory filing category.
2025-08-18 Korean
반기보고서 (2025.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for Onconic Therapeutics Inc., covering the period from January 1, 2025, to June 30, 2025. It contains detailed financial information, business operations, management discussions, and corporate governance details, which are characteristic of an interim/quarterly report. It is not a mere announcement or certification, as it provides substantive financial and operational data. H1 2025
2025-08-11 Korean
투자판단관련주요경영사항(임상시험계획변경승인신청) (자큐보정 JP-1366 약물상호작용 확인을 위한 1상 임상시험계획승인(변경승인) 신청)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from Onconic Therapeutics regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically an application for a change in clinical trial approval (임상시험계획 변경승인신청) for their drug 'Zakubo' (JP-1366). This is a standard corporate disclosure for material events in South Korean financial markets. Since it does not fit into specific categories like M&A, dividends, or financial reports, and is a formal regulatory disclosure of a material business event, it is classified as a Regulatory Filing (RNS).
2025-08-01 Korean
투자판단관련주요경영사항(임상시험계획변경승인신청) (네수파립의 위암 제1b/w상 임상시험계획승인(변경승인)신청)
Regulatory Filings Classification · 100% confidence The document is a regulatory disclosure from Onconic Therapeutics regarding an application for a clinical trial plan amendment (IND) for their drug candidate, Nesuparib. It follows the standard format for 'Major Management Matters' (투자판단 관련 주요경영사항) common in Korean regulatory filings. Since it details a specific regulatory action regarding clinical trials and does not fit into the other specialized categories like financial reports or shareholder meetings, it is classified as a general regulatory filing.
2025-07-30 Korean

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.